Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

Havah Therapeutics

Status and phase

Completed

Phase 1

Conditions

Mammographic Density

Treatments

Drug: enobosarm

Study type

Interventional

Funder types

Industry

Identifiers

NCT03264651

CH02ST1

Details and patient eligibility

About

To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.

Full description

High mammographic breast density is a well recognized risk factor for the development of breast cancer and the masking of malignancy within the breast. Previous chemoprevention studies have revealed that only tamoxifen is efficacious in premenopausal women in the reduction of breast cancer. In order for this to occur mammographic density has to be reduced. Unfortunately the side effect profile of tamoxifen is such that not many women are taking up this therapeutic intervention. This trial is trying to establish a combination therapy to reduce mammographic breast density.

This phase 1 pilot study is combining oral enobosarm, a selective androgen receptor modulator, and oral anastrozole, an aromatase inhibitor, to study the impact of this combination treatment on mammographic breast density and breast elasticity. Safety and tolerability we also analyzed.

Enrollment

9 patients

Sex

Female

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Provision of written informed consent
Pre-menopausal levels of FSH/LH/E2 (follicle stimulating hormone, luteinizing hormone, oestrogen) according to the definition of "pre-menopausal range" for the laboratory involved
Have a Volpara Density volumetric breast density of >15.5% (combined average both breasts)
Breast pain in the previous month of equal to or greater than 40mm on a 100mm visual analogue pain scale
WBC ≥ 3.0 x 109/L, granulocytes ≥ 1.5 X 109/L and platelets ≥ 100 x 109/L.
AST/SGOT or ALT/SGPT ≤ 3 times ULN
eGFR> 60 ml/min/1.73m2
Negative pregnancy test in women of childbearing potential (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization), no more than 7 days before the first dose of study treatment;
For women of childbearing potential who are sexually active, agreement to use a highly effective, non-hormonal form of contraception during and for at least 6 months after completion of study treatment; OR, a fertile male partner willing and able to use effective non-hormonal means of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilization) during and for at least 6 months after completion of study treatment;

Exclusion criteria

Presence of breast cancer
Diabetes mellitus or glucose intolerance defined as a fasting glucose >6mmol/l
Previous or concomitant other (non-breast cancer) malignancy within the previous 5 years (other than skin cancer)
History of coronary artery disease
Systemic hormonal contraception
Risk of transmitting Human Immunodeficiency Virus or viral hepatitis via infected blood
Known hypersensitivity to any component of testosterone
Unable to comply with study requirements
Prolonged systemic corticosteroid treatment
Any investigational drugs
Systemic hormone replacement therapy
Pregnant or lactating women
Known liver disease
Current warfarin usage